Drugs / ABC/3TC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04493216 Background | Nov 2020 → Sep 2022 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABC/3TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493216 ↗ |
| Route | Oral | “ABC/3TC was available as abacavir 600 mg/lamivudine 300 mg tablet to be administered via oral route.” NCT04493216 ↗ |